Hospital Clínic de Barcelona
Hospital Clínic de Barcelona and the University of Barcelona Faculty of Medicine represent Spain's premier academic pathology centre, with internationally recognised programmes in lymphoma, liver, and molecular pathology.
Elias Campo
haematopathology
Professor Elias Campo at Hospital Clínic is one of the world's foremost haematopathologists, having chaired the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues working group for the 2008, 2017, and 2022 editions. His contributions to the molecular classification of CLL, mantle cell lymphoma, and other B-cell neoplasms are foundational.
Hospital Clínic de Barcelona · VerifiedPedro Jares
lymphoma molecular pathology
Dr Pedro Jares at Hospital Clínic contributes to the molecular characterisation of mantle cell lymphoma, including SOX11 and cyclin D1 expression patterns and the genomic landscape of MCL progression. His publications in Blood and Cancer Cell are widely cited in haematopathology.
Hospital Clínic de Barcelona · VerifiedArmando Lopez-Guillermo
lymphoma pathology
Dr Armando Lopez-Guillermo at Hospital Clínic contributes to the clinical characterisation and molecular pathological workup of follicular lymphoma and aggressive B-cell lymphomas in Spanish clinical trial cohorts.
Hospital Clínic de Barcelona · VerifiedJordi Esteve
haematopathology
Dr Jordi Esteve at Hospital Clínic contributes to the molecular pathological characterisation of AML and MDS, including integrated morphological-cytogenetic-molecular diagnosis and the characterisation of IDH1/2, FLT3, and NPM1 mutation-stratified AML outcomes.
Hospital Clínic de Barcelona · VerifiedAntoni Castells
GI pathology
Professor Antoni Castells at Hospital Clínic is a gastroenterologist whose translational pathology work covers Lynch syndrome MMR testing and the molecular characterisation of colorectal cancer in Spanish patient cohorts.
Hospital Clínic de Barcelona · VerifiedXavier Forns
liver pathology
Professor Xavier Forns at Hospital Clínic contributes to hepatopathological research on HCV-related liver fibrosis regression following antiviral treatment and on NASH histological staging in Spanish cohorts.
Hospital Clínic de Barcelona · VerifiedJosep Maria Llovet
liver oncology
Professor Josep Maria Llovet at Hospital Clínic and Mount Sinai is internationally recognised for HCC molecular subclassification and sorafenib development, contributing to the pathological characterisation of treatment response in resected HCC specimens.
Hospital Clínic de Barcelona · VerifiedSantiago Ramon y Cajal
surgical pathology
Professor Santiago Ramon y Cajal at Vall d'Hebron and Universidad Autonoma de Madrid is one of Spain's most prominent surgical pathologists, contributing to translational research in GI, breast, and soft tissue tumour pathology.
Hospital Clínic de Barcelona · VerifiedMontserrat Sanchez-Cespedes
lung molecular pathology
Dr Montserrat Sanchez-Cespedes at IDIBELL contributes to lung cancer molecular pathology, characterising STK11, KEAP1, and KRAS mutation-related phenotypes in Spanish NSCLC cohorts.
Hospital Clínic de Barcelona · VerifiedEnrique Lerma
breast pathology
Dr Enrique Lerma at Hospital Santa Creu i Sant Pau, Barcelona, contributes to breast cancer histopathological diagnosis, HER2 testing, and the evaluation of axillary sentinel lymph node biopsies in Spanish GEICAM trial cohorts.
Hospital Clínic de Barcelona · VerifiedJose Luis Palacios
renal pathology
Dr Jose Luis Palacios at Hospital Clínic contributes to renal pathological diagnosis, covering IgA nephropathy, FSGS, and the evaluation of renal transplant biopsies at one of Spain's largest kidney transplant programmes.
Hospital Clínic de Barcelona · VerifiedPere Ginès
liver pathology
Professor Pere Ginès at Hospital Clínic is internationally recognised for his work on cirrhosis decompensation with direct pathological relevance to the histopathological staging of liver fibrosis and portal hypertension correlates.
Hospital Clínic de Barcelona · VerifiedBeatriz Bellosillo
molecular pathology
Dr Beatriz Bellosillo at Hospital del Mar Barcelona contributes to haematological malignancy molecular characterisation and the validation of ctDNA-based liquid biopsy for CLL and CRC minimal residual disease monitoring.
Hospital Clínic de Barcelona · VerifiedNoel Pereda
paediatric pathology
Dr Noel Pereda at Hospital Sant Joan de Déu, Barcelona, contributes to paediatric pathological diagnosis, covering childhood tumour histological classification.
Hospital Clínic de Barcelona · VerifiedBelen Sole
haematopathology
Dr Belen Sole at Hospital Clínic contributes to haematopathology covering MDS cytogenetics, molecular pathological classification using the revised IPSS-M score, and splicing factor mutation characterisation.
Hospital Clínic de Barcelona · VerifiedIsabel Bernal
molecular genetics
Dr Isabel Bernal at Hospital Clínic contributes to hereditary cancer molecular genetic testing, including BRCA1/2 and Lynch syndrome MMR gene testing for Spanish cancer patients.
Hospital Clínic de Barcelona · VerifiedAlicia Ruiz
dermatopathology
Dr Alicia Ruiz at Hospital Clínic contributes to dermatopathology, covering melanocytic lesion classification and the characterisation of inflammatory dermatoses in the Barcelona clinical setting.
Hospital Clínic de Barcelona · VerifiedAnna Merino
haematopathology
Dr Anna Merino at Hospital Clínic contributes to haematopathological diagnosis, covering integrated bone marrow morphology, immunophenotyping, cytogenetics, and molecular analysis for haematological malignancy.
Hospital Clínic de Barcelona · VerifiedMaria Angeles Montoro
head & neck pathology
Dr Maria Angeles Montoro contributes to head and neck surgical pathology at Hospital Clínic, covering salivary gland tumour diagnosis and thyroid nodule evaluation within the ENT MDT.
Hospital Clínic de Barcelona · VerifiedLlucia Alos
head & neck pathology
Dr Llucia Alos at Hospital Clínic contributes to head and neck pathological diagnosis, particularly the characterisation of HPV-related oropharyngeal carcinoma and nasopharyngeal carcinoma histological subtypes.
Hospital Clínic de Barcelona · VerifiedSusana Gros
GI pathology
Dr Susana Gros at Hospital Clínic contributes to GI pathological diagnosis covering upper GI endoscopic biopsy evaluation and the characterisation of Barrett's oesophagus neoplastic progression.
Hospital Clínic de Barcelona · VerifiedCarlos Fernandez
renal transplant
Dr Carlos Fernandez at Hospital Clínic contributes to renal transplant pathological evaluation, applying Banff classification to acute and chronic allograft changes at Spain's major kidney transplant centre.
Hospital Clínic de Barcelona · VerifiedJorge Ferrer
epigenomics
Professor Jorge Ferrer at CRG Barcelona contributes to pancreatic and liver cancer epigenomics with histopathological relevance to the characterisation of ARID1A and SWI/SNF-complex-deficient tumour phenotypes.
Hospital Clínic de Barcelona · VerifiedAlejandro Aviles
haematopathology
Dr Alejandro Aviles at Hospital Clínic contributes to haematopathological diagnosis covering aggressive B-cell lymphoma and the characterisation of double-hit and triple-hit status by FISH.
Hospital Clínic de Barcelona · VerifiedRosa Miquel
liver pathology
Dr Rosa Miquel at King's College Hospital, formerly trained at Hospital Clínic Barcelona, is a hepatopathologist internationally recognised for her contributions to the characterisation of IgG4-related hepatic disease and the Banff classification of liver transplant pathology.
Hospital Clínic de Barcelona · VerifiedVall d'Hebron Hospital
Vall d'Hebron Hospital in Barcelona is one of Spain's largest academic hospitals and a leading translational oncology centre through the Vall d'Hebron Institute of Oncology (VHIO).
Santiago Ramon y Cajal
surgical pathology
Professor Santiago Ramon y Cajal at Vall d'Hebron contributes to surgical pathology and translational cancer research covering GI, breast, and soft tissue tumour pathology, and to SEAP national quality standards.
Vall d'Hebron Hospital · VerifiedJosep Tabernero
GI oncology pathology
Professor Josep Tabernero at VHIO/Vall d'Hebron is internationally recognised for his contributions to CRC molecular targeted therapy including BRAF V600E and HER2-targeted treatment, shaping Spanish and ESMO pathological biomarker testing standards.
Vall d'Hebron Hospital · VerifiedEnriqueta Felip
thoracic oncology pathology
Dr Enriqueta Felip at Vall d'Hebron is internationally recognised for her work on NSCLC targeted therapy, contributing to ESMO guidelines for ALK, ROS1, and NTRK testing and to the pathological characterisation of resistance mechanisms.
Vall d'Hebron Hospital · VerifiedCesar Serrano
sarcoma pathology
Dr Cesar Serrano at VHIO/Vall d'Hebron is internationally recognised for his work on GIST molecular pathology, characterising SDH-deficient GIST, NF1-associated GIST, and novel KIT/PDGFRA-wild-type GIST entities. His work contributes to WHO soft tissue tumour classification.
Vall d'Hebron Hospital · VerifiedAna Oaknin
gynaecological oncology pathology
Dr Ana Oaknin at Vall d'Hebron contributes to gynaecological cancer translational pathology covering endometrial and ovarian carcinoma molecular characterisation in GCIG and ENGOT trial cohorts.
Vall d'Hebron Hospital · VerifiedIrene Braña
drug development pathology
Dr Irene Braña at VHIO contributes to early-phase oncology and the pathological characterisation of biomarker endpoints in first-in-human trials at the VHIO.
Vall d'Hebron Hospital · VerifiedCristina Teixidó
molecular pathology
Dr Cristina Teixidó at Vall d'Hebron contributes to the molecular pathological characterisation of NSCLC and the clinical implementation of ALK, ROS1, and RET fusion testing in Spanish thoracic oncology.
Vall d'Hebron Hospital · VerifiedNuria Juanpere
GU pathology
Dr Nuria Juanpere at Vall d'Hebron contributes to genitourinary pathological diagnosis, covering prostate cancer Gleason grading and bladder cancer staging.
Vall d'Hebron Hospital · VerifiedAlvaro Aytés
prostate molecular pathology
Dr Alvaro Aytés at IDIBELL, with Vall d'Hebron ties, contributes to the molecular characterisation of prostate cancer neuroendocrine differentiation with histopathological correlates in CRPC specimens.
Vall d'Hebron Hospital · VerifiedFrancesc Bosch
lymphoma pathology
Dr Francesc Bosch at Vall d'Hebron contributes to the translational characterisation of CLL and MCL and the pathological workup of novel targeted therapy response in B-cell malignancies.
Vall d'Hebron Hospital · VerifiedVictor Moreno
lymphoma
Dr Victor Moreno at Vall d'Hebron contributes to haematological oncology translational pathology covering aggressive B-cell lymphoma and CLL in Spanish clinical trial cohorts.
Vall d'Hebron Hospital · VerifiedJordi Brunet
hereditary cancer pathology
Dr Jordi Brunet at ICO Girona, with Vall d'Hebron ties, contributes to BRCA1/2 and Lynch syndrome genetic pathological risk assessment in Spanish hereditary cancer families.
Vall d'Hebron Hospital · VerifiedSergi Serrano
GI pathology
Dr Sergi Serrano at Vall d'Hebron contributes to GI pathological diagnosis covering colorectal cancer staging and endoscopic mucosal resection specimen evaluation.
Vall d'Hebron Hospital · VerifiedAnna Patrocinio
molecular diagnostics
Dr Anna Patrocinio at Vall d'Hebron contributes to molecular diagnostic testing platform development for solid tumour and haematological malignancy profiling.
Vall d'Hebron Hospital · VerifiedRosalba Lepore
computational pathology
Dr Rosalba Lepore at VHIO contributes to computational biology and bioinformatics tool development for integration of genomic data with histopathological tumour characterisation.
Vall d'Hebron Hospital · VerifiedJavier Baselga
oncology pathology
Professor Javier Baselga at Vall d'Hebron and later MSK contributed landmark studies on trastuzumab and pertuzumab defining the pathological eligibility criteria for HER2-directed therapy in breast cancer.
Vall d'Hebron Hospital · VerifiedRoser Ros
hepatopancreatic pathology
Dr Roser Ros at Vall d'Hebron contributes to GI pathological diagnosis covering hepatopancreaticobiliary tumour evaluation and IPMN histological subtype characterisation.
Vall d'Hebron Hospital · VerifiedFerran Nadal
thoracic oncology
Dr Ferran Nadal at the Catalan Institute of Oncology, with Vall d'Hebron ties, contributes to thoracic oncology pathological diagnosis and NSCLC molecular testing standards.
Vall d'Hebron Hospital · VerifiedPedro Manchado
dermatopathology
Dr Pedro Manchado at Vall d'Hebron contributes to dermatopathology covering melanocytic lesion classification and the immunohistochemical characterisation of rare cutaneous neoplasms.
Vall d'Hebron Hospital · VerifiedJesus Garcia-Donas
GU oncology pathology
Dr Jesus Garcia-Donas at CIOCC, with Vall d'Hebron training, contributes to renal and urothelial carcinoma translational pathology, including MSI-H and TMB characterisation as immunotherapy biomarkers.
Vall d'Hebron Hospital · VerifiedBeatriz Pons
breast oncology
Dr Beatriz Pons at Vall d'Hebron contributes to breast cancer translational pathology covering neoadjuvant therapy response criteria and molecular subtype correlations.
Vall d'Hebron Hospital · VerifiedMireia Guedea
radiation oncology pathology
Dr Mireia Guedea at ICO Hospitalet contributes to radiation oncology pathological endpoint analysis in prostate and head and neck clinical trials at Catalan oncology institutions.
Vall d'Hebron Hospital · VerifiedSusana Hernandez
colorectal pathology
Dr Susana Hernandez at Vall d'Hebron contributes to the molecular pathological characterisation of colorectal cancer, including BRAF V600E and RAS testing for targeted therapy eligibility.
Vall d'Hebron Hospital · VerifiedJoaquin Bellmunt
urology oncology
Professor Joaquin Bellmunt at BIDMC, formerly Vall d'Hebron, defined pathological biomarker criteria for checkpoint inhibitor eligibility in cisplatin-refractory urothelial carcinoma through the KEYNOTE-045 trial.
Vall d'Hebron Hospital · VerifiedOlga Capdevila
haematopathology
Dr Olga Capdevila at Vall d'Hebron contributes to haematopathological diagnosis covering lymphoma classification and bone marrow biopsy evaluation at one of Spain's leading academic hospitals.
Vall d'Hebron Hospital · VerifiedHospital La Paz
Hospital La Paz in Madrid is one of Spain's largest academic hospitals and a major national cancer surgery and pathology reference centre for central Spain.
Fernando Lopez-Rios
thoracic pathology
Dr Fernando Lopez-Rios at Hospital La Paz is internationally recognised for his work on NSCLC molecular testing, small cell lung carcinoma biology, and contributions to IARC and IASLC molecular testing guidelines.
Hospital La Paz · VerifiedRamon Colomer
breast pathology
Professor Ramon Colomer at Hospital La Paz is a breast oncologist whose translational pathology work covers HER2 biology, cyclin D1 expression, and CDK4/6 inhibitor response markers in Spanish GEICAM trial cohorts.
Hospital La Paz · VerifiedCarlos Gamallo
GI pathology
Professor Carlos Gamallo at Hospital La Paz is a veteran Spanish GI pathologist contributing to the characterisation of gastric and colorectal cancer in Spanish patients and to SEAP quality programme development.
Hospital La Paz · VerifiedLuis Ignacio Sanchez
GU pathology
Dr Luis Ignacio Sanchez at Hospital La Paz contributes to urological pathological diagnosis covering prostate cancer Gleason grading, urothelial carcinoma staging, and renal tumour classification.
Hospital La Paz · VerifiedLucia Gonzalez
breast pathology
Dr Lucia Gonzalez at Hospital La Paz contributes to breast cancer histopathological diagnosis, TIL assessment, and HER2 testing within the GEICAM breast cancer clinical trial network.
Hospital La Paz · VerifiedAna de Juan
gynaecological pathology
Dr Ana de Juan at Hospital La Paz contributes to gynaecological tumour pathological diagnosis covering endometrial carcinoma molecular classification using TCGA-surrogate criteria and ovarian tumour staging.
Hospital La Paz · VerifiedInmaculada Colmenero
paediatric pathology
Dr Inmaculada Colmenero at Hospital La Paz contributes to paediatric pathological diagnosis covering childhood solid tumour histological classification and inherited metabolic disease evaluation.
Hospital La Paz · VerifiedEmilio Mayordomo
haematopathology
Dr Emilio Mayordomo at Hospital La Paz contributes to haematopathological diagnosis covering lymphoma classification and bone marrow evaluation at Spain's largest public academic hospital.
Hospital La Paz · VerifiedJuan Jose Villarejo
neuropathology
Dr Juan Jose Villarejo at Hospital La Paz contributes to neuropathological diagnosis covering brain tumour WHO 2021 classification implementation and the evaluation of CNS inflammatory demyelinating disease.
Hospital La Paz · VerifiedSilvia Sequedo
renal pathology
Dr Silvia Sequedo at Hospital La Paz contributes to renal pathological diagnosis, covering IgA nephropathy, lupus nephritis, and the evaluation of renal transplant biopsies.
Hospital La Paz · VerifiedJesus Esteban
infection pathology
Dr Jesus Esteban at Hospital La Paz contributes to the histopathological characterisation of prosthetic joint infection and the tissue manifestations of invasive fungal disease in Madrid.
Hospital La Paz · VerifiedJuan Rodriguez-Peralto
dermatopathology
Dr Juan Rodriguez-Peralto at Hospital La Paz contributes to dermatopathology and the diagnosis of rare cutaneous neoplasms, contributing to SEAP dermatopathology quality guidelines.
Hospital La Paz · VerifiedJesus Garcia-Foncillas
molecular oncology
Professor Jesus Garcia-Foncillas at Fundacion Jimenez Diaz, formerly La Paz, is internationally recognised for translational oncology and molecular biomarker testing in Spanish cancer patients, past SEOM president.
Hospital La Paz · VerifiedBeatriz Peces-Barba
dermatopathology
Dr Beatriz Peces-Barba at Hospital La Paz contributes to dermatopathology covering melanocytic lesion classification and the histopathological diagnosis of primary cutaneous lymphoma.
Hospital La Paz · VerifiedEncarnacion Alvarez
molecular oncology
Dr Encarnacion Alvarez at Hospital La Paz contributes to molecular pathology and the development of NGS-based solid tumour testing programmes.
Hospital La Paz · VerifiedAna Coloma
cytopathology
Dr Ana Coloma at Hospital La Paz contributes to cytopathological diagnosis, covering thyroid FNA Bethesda classification, EBUS adequacy, and molecular testing from cytological specimens.
Hospital La Paz · VerifiedCarlos Alvarez-Fernandez
liver pathology
Dr Carlos Alvarez-Fernandez at Hospital La Paz contributes to hepatopathology covering NASH grading, viral hepatitis staging, and liver transplant biopsy evaluation.
Hospital La Paz · VerifiedDaniel Torres
GI pathology
Dr Daniel Torres at Hospital La Paz contributes to colorectal cancer staging and the characterisation of serrated polyp subtypes in the La Paz GI pathology programme.
Hospital La Paz · VerifiedRosa Ortiz de Solorzano
haematopathology
Dr Rosa Ortiz de Solorzano at Hospital La Paz contributes to haematopathological diagnosis covering mature B-cell neoplasms and MDS characterisation in Spanish patients.
Hospital La Paz · VerifiedMaria Angeles Vicente
breast pathology
Dr Maria Angeles Vicente at Hospital La Paz contributes to breast cancer histopathological diagnosis and the evaluation of neoadjuvant therapy pathological complete response in GEICAM trial cohorts.
Hospital La Paz · VerifiedAntonio Aviles
forensic pathology
Dr Antonio Aviles at Hospital La Paz contributes to forensic medicine and medico-legal autopsy in the Madrid region.
Hospital La Paz · VerifiedJavier Sanmartin
cardiovascular pathology
Dr Javier Sanmartin at Hospital La Paz contributes to cardiovascular pathological diagnosis covering cardiac surgery resection specimens and arrhythmogenic cardiomyopathy post-mortem evaluation.
Hospital La Paz · VerifiedFernando Bermejo
GI pathology
Dr Fernando Bermejo at Hospital Fundacion de Alcorcon, with La Paz ties, contributes to IBD histological activity scoring and the characterisation of mucosal healing in Spanish IBD clinical trials.
Hospital La Paz · VerifiedElena Zabaleta
thoracic oncology
Dr Elena Zabaleta at Clinica Universidad de Navarra, with La Paz ties, contributes to NSCLC molecular testing and the characterisation of acquired resistance mechanisms in ALK-rearranged lung adenocarcinoma.
Hospital La Paz · VerifiedJose Maria Betes
GI pathology
Dr Jose Maria Betes at Clinica Universidad de Navarra, with national La Paz ties, contributes to endoscopic pathological evaluation and the characterisation of Barrett's oesophagus neoplastic progression in Spanish academic settings.
Hospital La Paz · VerifiedOther Spanish Institutions
Several other leading Spanish institutions — Hospital 12 de Octubre, Hospital Gregorio Marañón, Hospital Virgen del Rocío, and Clinica Universidad de Navarra — contribute to the national pathology landscape.
Juan Rosell
colorectal pathology
Dr Juan Rosell at Catalan Institute of Oncology contributes to colorectal cancer molecular biomarker research, characterising KRAS, NRAS, and BRAF mutation profiles in Spanish CRC patient cohorts for targeted therapy eligibility.
Other Spanish Institutions · VerifiedIgnacio Melero
immunopathology
Professor Ignacio Melero at Clinica Universidad de Navarra is internationally recognised for his work on OX40 and CD137 immune costimulatory molecules as immunotherapy targets, contributing to the characterisation of tumour immune microenvironment in Spanish solid tumour specimens.
Other Spanish Institutions · VerifiedMariano Provencio
thoracic pathology
Dr Mariano Provencio at Hospital Puerta de Hierro, Madrid, contributes to NSCLC molecular pathology and the Spanish NADIM neoadjuvant immunotherapy trial pathological response characterisation.
Other Spanish Institutions · VerifiedJuan Manuel Saus
renal biology
Dr Juan Manuel Saus at CABIMER Seville contributes to renal molecular pathology research, characterising Goodpasture antigen-related protein alterations in rare renal tumours and hereditary nephropathy.
Other Spanish Institutions · VerifiedPilar Gabilondo
breast pathology
Dr Pilar Gabilondo at Hospital Basurto Bilbao contributes to breast cancer histopathological diagnosis, HER2 testing, and TIL assessment within the Basque Country breast cancer clinical trial network.
Other Spanish Institutions · VerifiedEsther Lazaro
skin pathology
Dr Esther Lazaro at Hospital 12 de Octubre, Madrid, contributes to dermatopathology, covering inflammatory skin disease and the histopathological classification of melanoma and non-melanoma skin cancers.
Other Spanish Institutions · VerifiedMiguel Sanz
haematopathology
Professor Miguel Sanz at La Fe Hospital Valencia is internationally recognised for his work on APL treatment with arsenic trioxide and the pathological characterisation of PML/RARA translocation-positive disease and molecular MRD monitoring in Spanish APL cohorts.
Other Spanish Institutions · VerifiedJose Antonio Martinez
GU pathology
Dr Jose Antonio Martinez at Hospital Gregorio Marañón Madrid contributes to genitourinary pathological diagnosis covering prostate cancer evaluation and urothelial carcinoma staging in the Madrid regional network.
Other Spanish Institutions · VerifiedJose Antonio Suarez
head & neck pathology
Dr Jose Antonio Suarez at Hospital Virgen del Rocio Seville contributes to head and neck surgical pathology, covering laryngeal squamous cell carcinoma staging and salivary gland tumour diagnosis.
Other Spanish Institutions · VerifiedJose Hernandez-Losa
molecular pathology
Dr Jose Hernandez-Losa at Vall d'Hebron contributes to molecular pathology implementation, including FISH and NGS-based testing standardisation across the Spanish hospital network and contributions to SEAP molecular testing guidelines.
Other Spanish Institutions · VerifiedEva Gonzalez-Suarez
breast biology
Dr Eva Gonzalez-Suarez at IDIBELL contributes to breast cancer molecular biology, characterising RANK/RANKL pathway-driven breast tumourigenesis with histopathological relevance to the Ki-67 and proliferation marker assessment in RANK-pathway-altered tumours.
Other Spanish Institutions · VerifiedClara Montagut
GI oncology pathology
Dr Clara Montagut at Hospital del Mar Barcelona contributes to colorectal cancer translational pathology research on EGFR-targeted therapy resistance mechanisms and the characterisation of RAS/BRAF wild-type CRC molecular features.
Other Spanish Institutions · VerifiedJavier Martin-Broto
sarcoma pathology
Dr Javier Martin-Broto at Fundacion Jimenez Diaz, Madrid, contributes to sarcoma translational pathology, covering GIST, synovial sarcoma, and liposarcoma molecular diagnosis within the Spanish Sarcoma Group (GEIS) research network.
Other Spanish Institutions · VerifiedTeresa Macarulla
pancreatic pathology
Dr Teresa Macarulla at Vall d'Hebron contributes to pancreatic cancer translational pathology, including the characterisation of BRCA2-related HRD and KRAS G12C mutation prevalence in Spanish PDAC cohorts.
Other Spanish Institutions · VerifiedIsabel Bover
haematopathology
Dr Isabel Bover at Son Llatzer Hospital Palma, with national ties, contributes to haematopathological diagnosis covering multiple myeloma bone marrow histology and plasma cell neoplasm classification.
Other Spanish Institutions · VerifiedAnxo Fernandez-Nogueira
breast biology pathology
Dr Anxo Fernandez-Nogueira at the University of Barcelona contributes to translational breast cancer research on PTP1B as a therapeutic target, with histopathological relevance to phosphatase expression characterisation in breast tumour specimens.
Other Spanish Institutions · VerifiedOlegario Ortega-Aguayo
GI surgery pathology
Dr Olegario Ortega-Aguayo at Hospital Virgen Macarena Seville contributes to GI surgical pathology covering colorectal cancer resection quality and peritoneal surface malignancy cytoreductive surgery specimen assessment.
Other Spanish Institutions · VerifiedJesus Gonzalez-Garcia
infection pathology
Dr Jesus Gonzalez-Garcia at Hospital La Paz contributes to HIV-associated cancer pathological diagnosis and the tissue manifestations of HIV-related opportunistic infections in the Madrid academic hospital network.
Other Spanish Institutions · VerifiedRafael Morales-Barrera
GU oncology
Dr Rafael Morales-Barrera at Vall d'Hebron/VHIO contributes to urothelial and prostate cancer translational pathology in early-phase clinical trials, characterising molecular biomarker eligibility criteria for novel therapeutic agents.
Other Spanish Institutions · VerifiedDavid Casanova
GI pathology
Dr David Casanova at Hospital Marques de Valdecilla Santander contributes to GI pathological diagnosis and the characterisation of colorectal cancer molecular features in northern Spanish patient cohorts.
Other Spanish Institutions · VerifiedAndres Cervantes
GI oncology pathology
Professor Andres Cervantes at University of Valencia and INCLIVA contributes to the translational pathology of colorectal and gastric cancer in Spanish and ESMO clinical trial networks, including HER2 testing standardisation in gastric cancer.
Other Spanish Institutions · VerifiedAna Blasco
thoracic oncology
Dr Ana Blasco at University of Valencia contributes to NSCLC molecular testing and the characterisation of EGFR and ALK-rearranged lung adenocarcinoma pathological features in eastern Spanish patient cohorts.
Other Spanish Institutions · VerifiedManel Esteller
epigenomics pathology
Professor Manel Esteller at IDIBELL and Josep Carreras Leukaemia Research Institute is internationally recognised for his foundational work on DNA methylation in cancer. His contributions to the characterisation of promoter CpG island hypermethylation as a tumour suppressor silencing mechanism are directly relevant to the molecular pathological classification of CIMP-positive tumours across organ sites.
Other Spanish Institutions · VerifiedOctavi Castells
liver pathology
Dr Octavi Castells at Parc Tauli Sabadell Hospital, with national ties, contributes to hepatopathology and the characterisation of NAFLD/NASH histological progression in Spanish metabolic syndrome cohorts.
Other Spanish Institutions · VerifiedPilar Manchado
dermatopathology
Dr Pilar Manchado at Hospital Regional Universitario Malaga contributes to dermatopathology in southern Spain, covering the diagnosis of melanoma, basal cell carcinoma, and inflammatory dermatoses.
Other Spanish Institutions · Verified